DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.400-1.500 for the period, compared to the consensus EPS estimate of 1.420. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday. UBS Group cut their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Piper Sandler raised their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Finally, Mizuho cut their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $13.46.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY traded down $0.61 during midday trading on Thursday, reaching $13.17. 5,502,740 shares of the company’s stock traded hands, compared to its average volume of 5,046,330. The company has a fifty day simple moving average of $11.68 and a two-hundred day simple moving average of $11.88. DENTSPLY SIRONA has a 1 year low of $9.40 and a 1 year high of $14.86. The company has a market cap of $2.64 billion, a P/E ratio of -4.18, a PEG ratio of 1.70 and a beta of 0.85. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.35 by $0.17. The company had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael J. Barber purchased 15,175 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director owned 55,943 shares of the company’s stock, valued at $552,716.84. This represents a 37.22% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian P. Mckeon acquired 10,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $101,200. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 35,160 shares of company stock worth $351,179 in the last 90 days. Insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its stake in DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after buying an additional 6,970,086 shares during the period. Armistice Capital LLC raised its holdings in shares of DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after buying an additional 5,234,587 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after acquiring an additional 4,003,606 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the period. Finally, Marshall Wace LLP boosted its holdings in DENTSPLY SIRONA by 1,032.5% during the 4th quarter. Marshall Wace LLP now owns 2,236,786 shares of the medical instruments supplier’s stock valued at $25,566,000 after acquiring an additional 2,039,280 shares during the period. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.